- Home
- FLWS vs CBIO Comparison
FLWS vs CBIO Comparison
Compare FLWS & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLWS
- CBIO
- Stock Information
- Founded
- FLWS 1976
- CBIO 2003
- Country
- FLWS United States
- CBIO United States
- Employees
- FLWS N/A
- CBIO N/A
- Industry
- FLWS Other Specialty Stores
- CBIO
- Sector
- FLWS Consumer Discretionary
- CBIO
- Exchange
- FLWS Nasdaq
- CBIO Nasdaq
- Market Cap
- FLWS 347.1M
- CBIO 308.0M
- IPO Year
- FLWS 1999
- CBIO N/A
- Fundamental
- Price
- FLWS $5.60
- CBIO $14.29
- Analyst Decision
- FLWS Hold
- CBIO Strong Buy
- Analyst Count
- FLWS 1
- CBIO 5
- Target Price
- FLWS $7.50
- CBIO $25.60
- AVG Volume (30 Days)
- FLWS 344.9K
- CBIO 97.6K
- Earning Date
- FLWS 09-04-2025
- CBIO 07-31-2025
- Dividend Yield
- FLWS N/A
- CBIO N/A
- EPS Growth
- FLWS N/A
- CBIO N/A
- EPS
- FLWS N/A
- CBIO N/A
- Revenue
- FLWS $1,709,948,000.00
- CBIO N/A
- Revenue This Year
- FLWS N/A
- CBIO N/A
- Revenue Next Year
- FLWS N/A
- CBIO N/A
- P/E Ratio
- FLWS N/A
- CBIO N/A
- Revenue Growth
- FLWS N/A
- CBIO N/A
- 52 Week Low
- FLWS $3.86
- CBIO $10.83
- 52 Week High
- FLWS $9.24
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- FLWS 50.17
- CBIO 52.92
- Support Level
- FLWS $5.37
- CBIO $13.50
- Resistance Level
- FLWS $5.58
- CBIO $16.00
- Average True Range (ATR)
- FLWS 0.22
- CBIO 0.79
- MACD
- FLWS 0.00
- CBIO 0.16
- Stochastic Oscillator
- FLWS 63.49
- CBIO 39.68
About FLWS 1-800-FLOWERS.COM Inc.
1-800-Flowers.com Inc is a provider of gifts designed to help customers express, connect, and celebrate. The company's e-commerce business platform features all brands, including 1-800-Flowers.com, 1-800-Baskets.com, Cheryl's Cookies, Harry and David, PersonalizationMall.com, Shari's Berries, FruitBouquets.com, Moose Munch, The Popcorn Factory, Wolferman's Bakery, Stock Yards, and Simply Chocolate. The company's business segments are; Consumer Floral and Gifts, BloomNet, and Gourmet Foods & Gift Baskets. The maximum revenue for the company is generated from its Gourmet Foods & Gift Baskets segment.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.